Evidence map›Paper›PMID 38649594›Full record

ArticleAnnals of hematology2024

Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG).

Huayuan Zhu, Xiao Lu, Xiaoping Zhang, Haiying Hua, Jie Zhang, Yuqing Miao, Weiying Gu, Min Xu, Xuzhang Lu, Bingzong Li and 19 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 2 countries.

Huayuan ZhuDepartment of Hematology, Lymphoma Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. huayuan.zhu@hotmail.com.
Xiao LuDepartment of Hematology, Lymphoma Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Xiaoping ZhangDepartment of Hematology, The Affiliated Zhongda Hospital of Southeast University Medical College, Nanjing, 210044, China.
Haiying HuaDepartment of Hematology, Wuxi Third People's Hospital, Wuxi, 214045, China.
Jie ZhangDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, 224006, China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou and The Third Affiliated Hospital of Soochow University, Changzhou, 213004, China.
Min XuDepartment of Hematology, Zhangjiagang First Affiliated Hospital of Soochow University, Zhangjiagang, 215699, China.
Xuzhang LuDepartment of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, 213004, China.
Bingzong LiDepartment of Hematology, the Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Chunling WangDepartment of Hematology, The First People's Hospital of Huai'an, Huai'an, 223399, China.
Haiwen NiDepartment of Hematology, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, 210004, China.
Jun QianDepartment of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, China.
Jinning ShiDepartment of Hematology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211199, China.
Maozhong XuDepartment of Hematology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, 214433, China.
Guangqi WuDepartment of Hematology, The First People's Hospital of Suqian, Suqian, 223812, China.
Yunping ZhangDepartment of Hematology, The Affiliated Yixing Hospital of Jiangsu University, Yixing, 214206, China.
Qiudan ShenDepartment of Hematology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215008, China.
Zhi WangDepartment of Hematology, Wuxi Second People's Hospital, Wuxi, 214001, China.
Jianfeng ZhuDepartment of Hematology, The People's Hospital of Taizhou, Taizhou, 225399, China.
Zhen ChengDepartment of Hematology, Taicang Hospital Affiliated to Soochow University, Taicang, 215488, China.
Wanchuan ZhuangDepartment of Hematology, The Second People's Hospital of Lianyungang, Lianyungang, 222002, China.
Guoqiang LinDepartment of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital, Huai'an, 223022, China.
Yongjun HuDepartment of Hematology, Huaiyin Hospital of Huai'an, Huai'an, 223399, China.
Qiurong ShanDepartment of Hematology, Shuyang Traditional Chinese Medicine Hospital, Shuyang, 223614, China.
Yifei ChenDepartment of Hematology, Jiangdu People's Hospital of Yangzhou, Yangzhou, 225202, China.
Hongchun QiuDepartment of Hematology, The Third People's Hospital of Kunshan, Kunshan, 215316, China.
Jianyong LiDepartment of Hematology, Lymphoma Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. lijianyonglm@126.com.
Wenyu ShiDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, 226001, China. shiwenyu@hotmail.com.
Nanjing Medical University · CNJiangsu University · CNJiangyin People's Hospital · CNSoochow University · CNAffiliated Hospital of Nantong University · CNAnyang Hospital of Traditional Chinese Medicine · CNHuaian First People’s Hospital · CNJiangsu Province Hospital · CNNanjing Traditional Chinese Medicine Hospital · CNNantong University · CNNordic Lymphoma Group · DKSecond People’s Hospital of Huai’an · CNSuzhou Municipal Hospital · CNThe First People's Hospital of Changzhou · CNThe First People’s Hospital of Lianyungang · CNWuxi Third People's Hospital · CNXian Yang Central Hospital · CNXuzhou Medical College · CNYancheng First People's Hospital · CNYangzhou University · CN

Funding

Jiangsu Province Capability Improvement Project through Science，Technology and Education ZDXK202209National Natural Science Foundation of China No.82170166
6 · The paper itself

Abstract

Elderly patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we retrospectively described the clinical features and outcomes of the first time infection of Omicron SARS-CoV-2 in 364 elderly patients with lymphoma enrolled in Jiangsu Cooperative Lymphoma Group (JCLG) between November 2022 and April 2023 in China. Median age was 69 years (range 60-92). 54.4% (198/364) of patients were confirmed as severe and critical COVID-19 infection. In univariable analysis, Age > 70 years (OR 1.88, p = 0.003), with multiple comorbidities (OR 1.41, p = 0.005), aggressive lymphoma (OR 2.33, p < 0.001), active disease (progressive or relapsed/refractory, OR 2.02, p < 0.001), and active anti-lymphoma therapy (OR 1.90, p < 0.001) were associated with severe COVID-19. Multiple (three or more) lines of previous anti-lymphoma therapy (OR 3.84, p = 0.021) remained an adverse factor for severe COVID-19 in multivariable analysis. Moreover, CD20 antibody (Rituximab or Obinutuzumab)-based treatments within the last 6 months was associated with severe COVID-19 in the entire cohort (OR 3.42, p < 0.001). Continuous BTK inhibitors might be protective effect on the outcome of COVID-19 infection (OR 0.44, p = 0.043) in the indolent lymphoma cohort. Overall, 7.7% (28/364) of the patients ceased, multiple lines of previous anti-lymphoma therapy (OR 3.46, p = 0.016) remained an adverse factor for mortality.

Indexed as

COVID-19LymphomaSARS-CoV-2AgedAged, 80 and overChinaComorbidityFemaleHumansMaleMiddle AgedRetrospective StudiesRituximabRituximabBTK inhibitorsCD20 antibodyCLLCOVID-19Elderly patients with lymphomaOmicron SARS-CoV-2

Identifiers

PMID38649594
OpenAlexW4394993466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.